Assessing the emergence of resistance: The absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Rodríguez Rojas, Alexandro ^a   Maciá, María D ^b   Couce, Alejandro ^a   Gómez, Cristina ^b   Castañeda García, Alfredo ^a   Oliver, Antonio ^b   Blázquez, Jesús ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; IMIPENEM; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LETHALITY; LUNG INFECTION; LUNG INJURY; MOUSE; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; WILD TYPE; DRUG COMBINATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MULTIDRUG RESISTANCE; PHYSIOLOGY; REPRODUCTIVE FITNESS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FOSFOMYCIN; GENETIC FITNESS; IMIPENEM; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 77956325563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010193     Document Type: Article

References (52)

1. Falagas ME, Grammatikos AP, Michalopoulos A (2008) Potential of oldgeneration antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 6: 593-600.
2. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI (2008) Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 46: 1069-1077.
3. Suarez JE, Mendoza MC (1991) Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother 35: 791-795.
4. Chin NX, Neu NM, Neu HC (1986) Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli. Drugs Exp Clin Res 12: 943-947.
5. Olay T, Rodriguez A, Oliver LE, Vicente MV, Quecedo MC (1978) Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies. J Antimicrob Chemother 4: 569-576.
6. Tessier F, Quentin C (1997) In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 16: 159-162.
7. Visalli MA, Jacobs MR, Appelbaum PC (1998) Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 42: 953-955.
8. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI (2003) Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 47: 2850-2858.
9. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, et al. (2009) CTX-M-15- producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 64: 712-717.
10. Andersson DI, Levin BR (1999) The biological cost of antibiotic resistance. Curr Opin Microbiol 2: 489-493.
11. Andersson DI (2006) The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9: 461-465.
12. Zengel JM, Young R, Dennis PP, Nomura M (1977) Role of ribosomal protein S12 in peptide chain elongation: analysis of pleiotropic, streptomycin-resistant mutants of Escherichia coli. J Bacteriol 129: 1320-1329.
13. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51.
14. Kadner RJ, Winkler HH (1973) Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol 113: 895-900.
15. Kahan FM, Kahan JS, Cassidy PJ, Kropp H (1974) The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235: 364-386.
16. Cordaro JC, Melton T, Stratis JP, Atagun M, Gladding C, et al. (1976) Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate: sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol 128: 785-793.
17. Alos JI, Garcia-Pena P, Tamayo J (2007) [Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections]. Rev Esp Quimioter 20: 211-215.
18. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM (2003) In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 22 Suppl 2: 53-59.
19. Gismondo MR, Drago L, Fassina C, Garlaschi ML, Rosina M, et al. (1994) Escherichia coli: effect of fosfomycin trometamol on some urovirulence factors. J Chemother 6: 167-172.
20. Klein U, Pawelzik M, Opferkuch W (1985) Influence of beta-lactam antibiotics, fosfomycin and vancomycin on the adherence (hemagglutination) of Escherichia coli-containing different adhesins. Chemotherapy 31: 138-145.
21. Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, et al. (2010) Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 35: 333-337.
22. Shorr AF (2009) Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37: 1463-1469.
23. Blanc DS, Petignat C, Janin B, Bille J, Francioli P (1998) Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. Clin Microbiol Infect 4: 242-247.
24. Rodriguez-Rojas A, Blazquez J (2009) The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection. J Bacteriol 191: 844-850.
25. Bjorkman J, Nagaev I, Berg OG, Hughes D, Andersson DI (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287: 1479-1482.
26. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, et al. (2006) An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci U S A 103: 2833-2838.
27. Heydorn A, Ersboll BK, Hentzer M, Parsek MR, Givskov M, et al. (2000) Experimental reproducibility in flow-chamber biofilms. Microbiology 146 (Pt 10): 2409-2415.
28. DiGiandomenico A, Rao J, Harcher K, Zaidi TS, Gardner J, et al. (2007) Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 104: 4624-4629.
29. Mueller-Ortiz SL, Drouin SM, Wetsel RA (2004) The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 72: 2899-2906.
30. Yonezawa M, Sugiyama H, Kizawa K, Hori R, Mitsuyama J, et al. (2000) A new model of pulmonary superinfection with Aspergillus fumigatus and Pseudomonas aeruginosa in mice. J Infect Chemother 6: 155-161.
31. Johansen HK, Espersen F, Cryz SJ, Jr., Hougen HP, Fomsgaard A, et al. (1994) Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect Immun 62: 3146-3155.
32. Jones ME, Thomas SM, Rogers A (1994) Luria-Delbruck fluctuation experiments: design and analysis. Genetics 136: 1209-1216.
33. Foster PL (2006) Methods for determining spontaneous mutation rates. Methods Enzymol 409: 195-213.
34. Kawaguchi K, Hasunuma R, Kikuchi S, Ryll R, Morikawa K, et al. (2002) Time- and dose-dependent effect of fosfomycin on suppression of infectioninduced endotoxin shock in mice. Biol Pharm Bull 25: 1658-1661.
35. Haag R, Vomel W, Schaumann W (1981) [Comparison of in vitro methods for the determination of the activity of fosfomycin with the efficacy determined in experimentally infected mice (author's transl)]. Immun Infekt 9: 177-182.
36. Schindler J, Langsadl L (1979) Fosfomycin therapy of experimental infections in mice. Zentralbl Bakteriol Orig A 243: 136-139.
37. Castaneda-Garcia A, Rodriguez-Rojas A, Guelfo JR, Blazquez J (2009) The Glycerol-3-Phosphate Permease GlpT Is the Only Fosfomycin Transporter in Pseudomonas aeruginosa. J Bacteriol 191: 6968-6974.
38. Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, et al. (1995) Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166: 175-176.
39. CLSI (2006) CLSI. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard - 7th Edition. Wayne, PA: Clinical and Laboratory Standards Institute. pp CLSI M7-A7.
40. O'Toole GA, Kolter R (1998) Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol 28: 449-461.
41. Tsuruoka T, Miyata A, Yamada Y (1978) Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J Antibiot (Tokyo) 31: 192-201.
42. Lemieux MJ, Huang Y, Wang DN (2004) Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation. Res Microbiol 155: 623-629.
43. Schweizer HP, Po C (1996) Regulation of glycerol metabolism in Pseudomonas aeruginosa: characterization of the glpR repressor gene. J Bacteriol 178: 5215-5221.
44. Moya B, Juan C, Alberti S, Perez JL, Oliver A (2008) Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52: 3694-3700.
45. Strateva T, Yordanov D (2009) Pseudomonas aeruginosa - a Phenomenon of Bacterial Resistance. J Med Microbiol.
46. Oliver A, Canton R, Campo P, Baquero F, Blazquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 1251-1254.
47. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, et al. (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49: 3382-3386.
48. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, et al. (2008) Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 190: 7910-7917.
49. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI (2009) Fosfomycin for the treatment of infections caused by multidrug-resistant nonfermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents.
50. Ward H, Perron GG, Maclean RC (2009) The cost of multiple drug resistance in Pseudomonas aeruginosa. J Evol Biol 22: 997-1003.
51. Waite RD, Paccanaro A, Papakonstantinopoulou A, Hurst JM, Saqi M, et al. (2006) Clustering of Pseudomonas aeruginosa transcriptomes from planktonic cultures, developing and mature biofilms reveals distinct expression profiles. BMC Genomics 7: 162.
52. Waite RD, Papakonstantinopoulou A, Littler E, Curtis MA (2005) Transcriptome analysis of Pseudomonas aeruginosa growth: comparison of gene expression in planktonic cultures and developing and mature biofilms. J Bacteriol 187: 6571-6576.